IL18 and myocardial infarction: In the high-IL-18 group (n = 485), the primary outcome occurred in 188 participants (35.3%), and, of the secondary outcomes, all-cause mortality occurred in 87 (17.9%), cardiac death in 47 (9.7%), MI in 58 (12.0%), and PCI in 62 (12.8%).